Sign in
Not yet taking people in United StatesNo phase

Surgeon-modified stent grafts for complex aortic aneurysms, including after failed earlier repair

Tests custom-modified stent grafts in adults with complex aortic aneurysms.

Key facts

Who runs it
Jesse Manunga, MD
Where
Minneapolis, United StatesSee the site
Trial code
Registry title
Safety and Effectiveness of Surgeon-Modified Stent Grafts forTreatment of Complex Aortic Aneurysms
Status
Not yet recruiting
People taking part
25 people, planned
Started
1 Oct 2022
Expected to end
1 Oct 2032
Type of study
Interventional, 2 groups
Treatments tested
  • Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)
Record updated
6 October 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a complex aortic aneurysm (a bulge in the main body artery near the kidney or chest arteries). People whose earlier stent repair (EVAR) failed can also join. They are treated with stent grafts modified by the surgeon.

Age
18 years and older
Sex
All sexes
Disease stage
Thoracoabdominal, juxtarenal, pararenal or paravisceral aneurysm, or a failed earlier EVAR. The aneurysm must be large (over 5.5 cm (2.2 in) in men, 5 cm (2 in) in women, or 2 times the normal width), growing over 0.5 cm (0.2 in) in 6 months, causing symptoms, ruptured, or a saccular aneurysm with a high chance of rupture. The artery shape and size must fit the device.
Earlier treatment
A failed earlier EVAR repair (type IA endoleak or a growing aneurysm sac after the top seal is lost) is one way to join.

Main reasons for not taking part

  • The aneurysm can be treated with a commercially approved stent graft as labelled, or the person can join a manufacturer-sponsored device study at the site
  • ASA score of 6 or very high surgical death risk (31-70%)
  • Pregnant or breastfeeding
  • Baseline creatinine greater than 2.0 mg/dL (177 µmol/L), coagulopathy that cannot be corrected, unstable angina, or an infection
  • Allergy to device materials (such as titanium, PTFE), or to blood thinners or contrast dye that cannot be managed; connective tissue disorders such as Marfan Syndrome

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Age: ≥ 18 years old
  • The subject has one or more of the following:; An aneurysm with a maximum diameter of > 5.5 cm (in men) and 5 cm (in women) or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e, perpendicular to the centerline) measurements 2. Aneurysm with a history of growth > 0.5 cm in 6 months or clinically indicated for repair based on symptoms 3. Symptomatic aneurysm 4. Ruptured aneurysm 6. Failed previous EVAR defined as type IA endoleak or increase in aneurysm sac size in the setting of proximal seal loss 7. Saccular aneurysm deemed by the treating vascular specialist at significant risk for rupture 8. High risk for open surgical repair based on any of the factors below:; Anatomic i. Previous abdominal surgery ii. Previous left-sided thoracotomy (if the proposed open repair would require dissection of the thoracic aorta) iii. Previous aortic surgery b. Physiological high risk For this IDE, physiological risk will be assessed using two systems. First, this study will use the Society for Vascular Surgery (SVS)/American Association for Vascular Surgery (AAVS) medical comorbidity grading system recommended for use by the SVS to describe the severity of medical comorbidities in patients with complex aortic aneurysm disease. However, as the current SVS/AAVS grading system has yet to be validated in prospective studies or in a large cohort of patients treated for aortic disease, the American Association of Anesthesiologists grading system will also be utilized due to its widely adopted use and simplicity although it relies on subjective parameters and lacks specific metrics that affect outcomes
  • American Association of Anesthesiologists grading system: subjects with ASA scores of 3-5 will be considered for study inclusion though final subject approval will be at the discretion of the treating vascular specialist; subjects with ASA scores of 6 will be excluded
  • SVS/AAVS grading system: high risk (8-20% mortality risk) subjects will be considered for study inclusion though final subject approval will be at the discretion of the treating vascular specialist; prohibitive high risk (31-70% mortality risk) subjects will be excluded; Medical Inclusion Criteria
  • American Association of Anesthesiologists (ASA) physical status classification system: subjects with ASA scores of 1-5 will be considered for study inclusion though final subject approval will be at the discretion of the treating vascular specialist; subjects with ASA scores of 6 will be excluded; SVS/AAVS grading system: low risk (0.12-1% mortality risk), medium risk (1.7-4.9% mortality risk), and high risk (8-20% mortality risk) subjects will be considered for study inclusion though final subject approval will be at the discretion of the treating vascular specialist; prohibitive high risk (31-70% mortality risk) subjects will be excluded; Anatomical Inclusion Criteria
  • Iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices, or accessories, with or without use of a surgical conduit
  • Extent of aorta to be treated: infrarenal aortic aneurysms with < 10 mm neck length, juxtarenal or pararenal aneurysms that include 1 or 2 renal arteries; paravisceral and extent IV-V thoracoabdominal aneurysms, Extent I-III thoracoabdominal aneurysm including those patients requiring a carotid-left subclavian bypass in order to achieve, at least, 20 mm of proximal landing zone
  • Non-aneurysmal aortic segment proximal to the aneurysm (neck) with a:; Minimum neck length of 20 mm; Diameter in the range of 20 mm - 38 mm; Angle less than 60 degrees relative to the axis of the aneurysm; Angle less than 60 degrees relative to the axis of the suprarenal aorta
  • Minimum branch vessel diameter of 5 mm or greater Iliac artery distal fixation site greater than 45 mm in length and diameter in the range of 8 mm to 17 mm

Who cannot take part

  • Is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site with the exception of percutaneous aortic valve surgery
  • Subject has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned < 30 days of the endovascular repair
  • History of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome) with the exception of patients who have had prior open surgical aortic replacement where a surgical graft would serve as a "landing zone" for the investigational stent-graft Anatomical Exclusion Criteria; Significant occlusive disease, tortuosity, or calcification that would prevent endovascular access; Proximal neck length ≤20 mm; Proximal neck, measured outer wall to outer wall on a sectional image (CT); For use of Zenith Fenestrated: diameter >32 mm or <18 mm; For use of Zenith Alpha Thoracic: diameter >38 mm or <18 mm (for proximal and distal neck diameter); Zenith TX2 Dissection Endovascular graft: diameter 38 mm or <18 mm; Zenith Flex AAA endovascular graft: diameter >32 mm or < 18 mm; Proximal neck angulated more than 60 degrees relative to the long axis of the aneurysm; Proximal neck diameter changes over the length of the proximal seal zone >4 mm; Proximal seal site with a circumferential thrombus/atheroma; Iliac artery diameter, measured inner wall to inner wall on a sectional image (CT) <7.0 mm at any point along access length (prior to deployment); Ipsilateral iliac artery fixation site diameter, measured inner wall on a sectional image (CT) >21 mm at distal fixation site; Iliac artery distal fixation site <10 mm in length; Non-bifurcated segment of any artery to be stented < 15 mm in length; Artery to be stented with a maximum diameter <3 mm or >10 mm at the vessel ostium; Inability to maintain at least one patent hypogastric artery; Bilateral renal artery stenosis >80%; Superior mesenteric artery stenosis >80%
  • Any other circumstance or condition which, at the discretion of the sponsor-investigator, makes the patient unsuitable for inclusion Medical Exclusion Criteria
  • Known sensitivities or allergies to the materials of construction of the devices, including but not limited to titanium and PTFE
  • Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
  • Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest, or nocturnal angina)
  • Systemic or local infection that may increase the risk of endovascular graft infection
  • Baseline creatinine greater than 2.0 mg/dL
  • Age: < 18 years old
  • Does not meet the above inclusion criteria
  • Can be treated in accordance with the instructions for use with a commercially approved and marketed endovascular prosthesis
  • Unwilling or unable to comply with the follow-up schedule
  • Inability or unwillingness of patient or patient's legally authorized representative to provide informed consent
  • Subject is pregnant or breastfeeding
  • Uncorrectable coagulopathy
  • Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment

Where in United States

  • Minneapolis Heart Institute FoundationMinneapolis, United StatesContact: JoAnne GoldmanNot yet recruiting

About the trial

What the trial wants to find out

The primary objective of the present study is to evaluate the safety, effectiveness, and clinical outcomes of surgeon-modified fenestrated stent grafts used to treat patients with failed previous infrarenal repairs (failed EVAR) and complex aortic aneurysms (thoracoabdominal, juxtarenal, pararenal, and paravisceral aneurysms).

The 2 groups in the trial

  • Thoracoabdominal aortic aneurysm extent I-IIITreatment being tested

    Thoracoabdominal aortic aneurysm extent I-III (proximal seal can be from the left carotid artery to directly after the left subclavian artery):

    Treatment: Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)

  • Failed EVARTreatment being tested

    Failed EVAR (defined as type IA endoleak or increase in aneurysm sac size in the setting of proximal seal loss)/juxtarenal/Pararenal/paravisceral/thoracoabdominal aortic aneurysm extent IV-V:

    Treatment: Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Safety and Effectiveness of Surgeon-Modified Fenestrated and Branched Endografts in Treating Subjects With Complex Aortic Aneurysms
Plain-language title
Surgeon-modified stent grafts for complex aortic aneurysms, including after failed earlier repairGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Publications
Record updated
6 October 2022